| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.52▲ | 5.53▲ | 5.58▼ | 5.43▲ | 5.77▼ |
| MA10 | 5.50▲ | 5.61▼ | 5.50▲ | 5.52▲ | 5.43▲ |
| MA20 | 5.51▲ | 5.48▲ | 5.41▲ | 5.70▼ | 4.91▲ |
| MA50 | 5.62▼ | 5.42▲ | 5.45▲ | 5.35▲ | 4.76▲ |
| MA100 | 5.49▲ | 5.46▲ | 5.60▼ | 4.90▲ | 5.59▼ |
| MA200 | 5.45▲ | 5.63▼ | 5.67▼ | 4.92▲ | 6.77▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.011▲ | -0.006▼ | 0.026▲ | -0.071▼ | 0.106▲ |
| RSI | 52.923▲ | 55.097▲ | 54.620▲ | 49.860▼ | 55.938▲ |
| STOCH | 63.426 | 41.700 | 74.907 | 37.992 | 56.485 |
| WILL %R | -8.333▲ | -34.694 | -28.333 | -50.562 | -51.095 |
| CCI | 229.573▲ | -22.046 | 40.774 | -33.483 | 38.504 |
|
Friday, February 13, 2026 04:19 PM
President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation—and specifically the BAF (SWI/SNF) chromatin remodeling complex—represents a broad and clinical ...
|
|
Tuesday, February 03, 2026 02:03 AM
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal ...
|
|
Tuesday, January 27, 2026 01:45 AM
Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/02/26 | 5.29 | 5.735 | 5.29 | 5.55 | 121,015 |
| 12/02/26 | 5.49 | 5.49 | 5.13 | 5.26 | 108,756 |
| 11/02/26 | 5.53 | 5.585 | 5.11 | 5.42 | 130,711 |
| 10/02/26 | 5.44 | 5.64 | 5.37 | 5.45 | 136,462 |
| 09/02/26 | 5.64 | 5.66 | 5.40 | 5.45 | 117,705 |
| 06/02/26 | 5.38 | 5.735 | 5.25 | 5.68 | 222,214 |
| 05/02/26 | 5.58 | 5.79 | 5.18 | 5.23 | 233,743 |
| 04/02/26 | 5.72 | 5.77 | 5.39 | 5.63 | 167,255 |
| 03/02/26 | 5.86 | 6.00 | 5.51 | 5.69 | 165,227 |
| 02/02/26 | 5.71 | 5.9825 | 5.7055 | 5.85 | 157,466 |
|
|
||||
|
|
||||
|
|